Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taisho: Worst Performance Since Establishment
May 28, 2007
- New JAS GL Calls For Diagnosis, Management of Dyslipidemia Based on LDL-C
May 28, 2007
- Shionogi: Sales Up 1.7% due to Royalty Income from Crestor
May 28, 2007
- SURVEY／Increased Number of Hospitals Discontinue Dialysis Therapy at Night
May 28, 2007
- Ono: Generics Hit Sales, Profits
May 28, 2007
- SEMINAR／Early Drug Treatment Recommended to Inhibit Joint Destruction: JCR
May 28, 2007
- Kyorin: Withdrawal of Tequin Abroad Hits Business
May 28, 2007
- MPC: Profits Up Despite 3.7% Fall in Sales
May 21, 2007
- REGULATORY NEWS IN BRIEF
May 21, 2007
- Tanabe Seiyaku: Strong Growth in Sales of Remicade Drives Business
May 21, 2007
- Latest Data from Enbrel All-Patient Surveillance Announced
May 21, 2007
- Santen: Strong Growth in Overseas Sales Drives Business
May 21, 2007
- Number of JP Drugs to Increase by 84
May 21, 2007
- Teijin: Pharm. Sales Up 7.1% to \113.1 Bil.
May 21, 2007
- Nippon Shinyaku Establishes Technology to Manufacture Long RNA Oligomers
May 21, 2007
- Kaken: Main Products Drive Overall Business
May 21, 2007
- Korosho to Select 10 Chukaku Hospitals, 30 Kyoten Hospitals for Clinical Trials
May 21, 2007
- Torii: Both Sales, Profits Down Due to Slump of Main Products
May 21, 2007
- R&D NEWS IN BRIEF
May 21, 2007
- Olympus: Sales Exceed \1 Tri. with 57.9% Increase in Operating Profits
May 21, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…